H. Lundbeck A/S (OTCMKTS:HLUYY) Stock Rating Lowered by Zacks Investment Research

H. Lundbeck A/S (OTCMKTS:HLUYYGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

HLUYY has been the subject of a number of other reports. Credit Suisse Group dropped their target price on H. Lundbeck A/S from 175.00 to 163.00 in a report on Thursday, February 10th. Barclays dropped their price target on H. Lundbeck A/S from 200.00 to 190.00 in a report on Tuesday, February 22nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $122.13.

Shares of HLUYY remained flat at $$23.40 during mid-day trading on Monday. The stock had a trading volume of 76 shares, compared to its average volume of 1,147. H. Lundbeck A/S has a fifty-two week low of $21.06 and a fifty-two week high of $32.52. The company has a quick ratio of 0.66, a current ratio of 0.98 and a debt-to-equity ratio of 0.26. The stock’s fifty day moving average price is $23.52 and its 200-day moving average price is $24.14. The stock has a market cap of $4.66 billion, a P/E ratio of 14.27 and a beta of 0.59.

About H. Lundbeck A/S (Get Rating)

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.

Recommended Stories

Get a free copy of the Zacks research report on H. Lundbeck A/S (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.